Published online Jan 19, 2024. doi: 10.5498/wjp.v14.i1.179
Peer-review started: November 1, 2023
First decision: November 17, 2023
Revised: November 27, 2023
Accepted: December 20, 2023
Article in press: December 20, 2023
Published online: January 19, 2024
Processing time: 79 Days and 5.7 Hours
Atrial fibrillation (AF), an irregular and rapid heart rate, is one of the most common types of cardiac arrhythmias. Research has shown that patients with AF are more prone to psychological problems than the general population. These problems increases the recurrence rate of AF while seriously affecting the quality of life, morbidity, and mortality rate of patients.
Anxiety and depression are the two most common mental health disorders worldwide. Studies have independently analyzed the risk of comorbidity with depression and anxiety in patients with AF. No study has systematically focused on the global epidemiology of these two mental disorders in patients with AF. A deeper understanding of the prevalence of comorbid depression and anxiety in these patients is essential in guiding clinical management.
To explore the prevalence of depression and anxiety in patients with AF.
Five databases were searched from their establishment until January 2023. Observational studies reporting the co-morbidity of AF with depression and anxiety–were included. STATA SE 15.1 was applied to analyze the data. Subgroup, meta-regression, and sensitivity analyses were performed to estimate study heterogeneity.
The prevalence rates of depression and anxiety in adults with AF were 24.3% and 14.5%, respectively. Among adult males with AF, the prevalence of depression and anxiety were 11.7% and 8.7%, respectively. This prevalence varied with sex, age and region; in females, it was 19.8% and 10.1%, and 40.3% and 33.6% in the older adults, respectively. The highest prevalence rate of depression and anxiety was observed in European (30.2%) and North American (19.8%) patients with AF. Furthermore, the prevalence varied according to the different evaluation scales.
We found that the prevalence of depression and anxiety among patients with AF was differentially distributed according to sex, region, and evaluation scales, suggesting the need for psychological interventions for patients with AF in clinical practice.
To explore this association further, future studies should focus on assessing the prevalence of depression and anxiety in patients with different types of AF, delineating the mechanisms of AF comorbidity with depression and anxiety using molecular biology and cellular immunology, and carrying out a large-scale observational epidemiological study to analyze its prevalence and provide a basis for clinical diagnosis and treatment.